BLA 761180 · Leo Pharma As
Adbry
Tralokinumab · Injection · Interleukin-13 Antagonist
NovelCDER novel approval, Dec 27, 2021: To treat moderate-to-severe atopic dermatitis
Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Dec 27, 2021
Approved uses
3
Original approval plus efficacy supplements
Registered trials
37
15 Phase 3, 5 recruiting
FAERS reports
6,706
923 serious, 90 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 17, 2025.
ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ADBRY is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ( 1 )
Mechanism: Tralokinumab-ldrm is a human IgG4 monoclonal antibody that specifically binds to human interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2). IL-13 is a naturally occurring cytokine of the Type 2 immune response. Tralokinumab-ldrm inhibits the bioactivity of IL-13 by blocking IL-13 interaction with IL-13Rα1/IL-4Rα receptor complex. Tralokinumab-ldrm inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE.
Therapeutic areas: Immunology and inflammation · Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 2024 Supplement 6 · Efficacy LabelLetter
- Dec 14, 2023 Supplement 1 · Efficacy LabelLetter
- Dec 27, 2021 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- ADBRY · TRALOKINUMAB 150MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tralokinumab" as an intervention, any sponsor and status, largest first.
- Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTENDPivotal-lookingCompleted
LEO PharmaIndustry
NCT03587805 · 1,672 participants · Start Mar 18, 2018 · Primary completion Jul 3, 2024
Drug: Tralokinumab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Mobile, Alabama; Fort Smith, Arkansas · 309 sites in all
- A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02161757 · 1,207 participants · Start Jun 13, 2014 · Primary completion Feb 28, 2017
Drug: Tralokinumab · For: Uncontrolled Asthma
Sites: Birmingham, Alabama; Phoenix, Arizona; Arcadia, California · 243 sites in all
- A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02194699 · 856 participants · Start Oct 30, 2014 · Primary completion May 10, 2017
Drug: Experimental: Tralokinumab · For: Uncontrolled Asthma
Sites: Birmingham, Alabama; Hoover, Alabama; Huntsville, Alabama · 234 sites in all
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)Pivotal-lookingCompleted
LEO PharmaIndustry
NCT03131648 · 802 participants · Start May 30, 2017 · Primary completion Aug 7, 2018
Drug: Tralokinumab; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 123 sites in all
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)Pivotal-lookingCompleted
LEO PharmaIndustry
NCT03160885 · 794 participants · Start Jun 12, 2017 · Primary completion Sep 4, 2018
Drug: Tralokinumab; Placebo · For: Atopic Dermatitis
Sites: Hot Springs, Arkansas; Encinitas, California; Fullerton, California · 115 sites in all
- A Safety and Efficacy Study of Tralokinumab in Adults With AsthmaPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT01402986 · 689 participants · Start Aug 2011 · Primary completion Jun 2013
Drug: Tralokinumab 300 mg, Q2W; Tralokinumab 300 mg, Q2/4W · For: Asthma
Sites: Rancho Mirage, California; Centennial, Colorado; New Haven, Connecticut · 89 sites in all
- A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary FibrosisPivotal-lookingTerminated
MedImmune LLCAstraZeneca (AZN)
NCT01629667 · 409 participants · Start Oct 2012 · Primary completion May 2015
Drug: Tralokinumab; Tralokinumab · For: Idiopathic Pulmonary Fibrosis
Sites: Phoenix, Arizona; La Jolla, California; Sacramento, California · 45 sites in all
- Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3Pivotal-lookingCompleted
LEO PharmaIndustry
NCT03363854 · 380 participants · Start Feb 22, 2018 · Primary completion Mar 8, 2019
Drug: Tralokinumab; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Encinitas, California; Fountain Valley, California · 66 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dermatitis atopic900
- drug ineffective856
- pruritus735
- rash496
- eczema465
- injection site pain432
- dry skin287
- injection site erythema239
- erythema225
- product use in unapproved indication223
- injection site pruritus208
- injection site swelling198
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 549 |
| 2023 | 1,020 |
| 2024 | 1,641 |
| 2025 | 1,894 |
| 2026 | 1,599 |
Recalls
1 FDA enforcement reports for this application.
Feb 10, 2026 · Class II · Ongoing
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Adbry (Tralokinumab-Ldrm)
2024 spending
$49.5M
Beneficiaries
2,251
12,832 claims
Per beneficiary
$22,003
$939.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $11,498,067 |
| 2023 | $31,579,580 |
| 2024 | $49,529,246 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Network Meta-Analysis
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Edwards SJ, Karner C, Jhita T, et al. · Health Technol Assess 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. · Br J Dermatol 2021 · Clinical Trial, Phase III, Multicenter Study
- Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
Wollenberg A, Howell MD, Guttman-Yassky E, et al. · J Allergy Clin Immunol 2019 · Clinical Trial, Phase II, Multicenter Study
- Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
Phinyo P, Krikeerati T, Vichara-Anont I, et al. · J Allergy Clin Immunol Pract 2024 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
Silverberg JI, Thyssen JP, Fahrbach K, et al. · J Eur Acad Dermatol Venereol 2021 · Systematic Review, Network Meta-Analysis
Sponsor: Leo Pharma As
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.